Lab-Grown Gut Tissue Sprouts Its Own Nervous System in Just 14 Days

A team at Cincinnati Children's Hospital Medical Center has grown human gastrointestinal tissue up to 8 centimeters long, nearly ten times larger than organoids from earlier methods, complete with a spontaneously generated enteric nervous system capable of driving rhythmic muscle contractions. The work, published in Nature Biomedical Engineering, cuts the time to transplantation-ready tissue from 28 days to 14, and marks the first demonstration of innervated human gut organoids engrafting successfully in a living host.

Confined culture system produces centimeter-scale gut organoids

The advance rests on a deceptively simple engineering move. The team, led by Maxime Mahe and Holly Poling, designed 3D-printed tray-like scaffolds with narrow grooves. Multiple organoid spheroids are loaded into these grooves and physically confined, which encourages them to press against one another, fuse, and elongate into a continuous tube of tissue. They called this the confined culture system, or CCS.

The physical constraint does more than just increase size. When spheroids merge under confinement, the cellular signaling environment shifts in ways that accelerate maturation. The resulting tissues reached up to 8 cm in length within 14 days and covered all three major gastrointestinal regions: small intestine, colon, and stomach. Single-cell RNA sequencing and protein expression analysis confirmed that the tissues developed the full complement of cell types expected in adult human gut, including both excitatory and inhibitory neuron subtypes within the enteric nervous system.

"We are now able not only to generate complex gastrointestinal organoids at scale, but also to guide their differentiation into functional tissues with integrated enteric neuronal networks. By leveraging a defined growth environment, the intrinsic self-organization capacity of the cells drives the formation of tissue structures that closely resemble the human gastrointestinal tract."

• Maxime Mahe

A self-wiring nervous system changes what gut organoids can do

The enteric nervous system, often called the gut's "second brain," regulates motility, secretion, and fluid balance. Earlier approaches to building innervated gut tissue required assembling neural components separately, a multi-step "assembloid" strategy that was technically demanding and hard to scale. Previous work engineering human intestinal tissue with functional ENS showed the concept was feasible but relied on combining pluripotent-stem-cell-derived neural crest cells with developing organoids in a separate preparation step.

In the CCS tissues, the nervous system wires itself. Electrophysiological assays confirmed viable neural networks that respond to neurotransmitters and external stimuli. Organ bath assays, in which a strip of tissue is suspended in physiological fluid and its mechanical activity is recorded, showed rhythmic contractile activity comparable to adult human intestinal samples. Crucially, contractions were driven by the enteric nervous system itself, not by passive muscle tone. Jim Wells, a co-author, noted that "the emergence of a self-organized nervous system within these organoids is particularly important for further studies of neurodevelopmental disorders."

This spontaneous innervation matters enormously for disease modeling. Conditions like Hirschsprung's disease, in which enteric neurons fail to colonize part of the colon, and irritable bowel syndrome both involve the ENS directly. Researchers studying these conditions have long needed tissue that behaves neurologically like real gut, and gut organoids in disease research have increasingly shown advantages over conventional cell lines, but the absence of integrated neural circuitry has been a persistent gap.

Transplantation in rodents confirms neuromuscular function in a living host

The team adapted a surgical technique called a "tie-in" procedure to transplant the organoids into rodents, connecting them to the animal's existing gut so they would be exposed to luminal flow and mechanical forces. The transplanted tissues engrafted successfully and displayed neuromuscular activity consistent with native human intestinal tissue, a result that no prior organoid method had demonstrated at this scale.

This is a meaningful threshold. Showing that engineered tissue can survive and function inside a living organism is a prerequisite for any eventual clinical application. The rodent data do not prove the tissues are ready for human transplantation, but they establish a proof-of-concept that the CCS approach produces tissue with the structural and functional integrity needed to persist after implantation.

Gaps remaining before human clinical applications

The study is explicit about what the technology does not yet do. The transplantation work has only been performed in rodents; no human trials have been conducted or planned on a disclosed timeline. Growing a complete, full-sized human organ in the laboratory remains out of reach. The CCS tissues, while large by organoid standards at up to 8 cm, are still segments rather than whole organs.

Standard limitations of organoid platforms also apply here. As reviewed in work on organoid model complexity limitations, most organoid systems still lack immune cells, vasculature, and a resident microbiome, all of which shape how the real gut behaves in health and disease. The CCS tissues are no exception on those counts. Separately, current intestinal organoid co-culture models frequently miss non-epithelial components that would be needed to fully replicate the gut's microenvironment for drug testing or transplantation purposes.

Scalable biomanufacturing and drug safety testing come next

Beyond transplantation, the team sees the CCS platform as a tool for drug safety screening, particularly for oral medications whose first point of contact with the body is the gastrointestinal wall. Pharmaceutical developers currently rely heavily on cell lines and animal models that do not accurately replicate human gut pharmacokinetics. Centimeter-scale human tissue with a functional nervous system could fill that gap.

The reproducibility gains also matter for basic science. One persistent frustration with organoid research has been batch-to-batch variability, which makes it difficult to compare results across experiments or labs. The defined geometry of the CCS grooves imposes a consistent growth environment that should, in principle, reduce that variability and make the system suitable for broader biomanufacturing applications. Funding for the work came from the National Institute of Diabetes and Digestive and Kidney Diseases and the Agence Nationale de la Recherche, and was primarily conducted at Cincinnati Children's and Nantes Université.